US0403341045 - Common Stock - After market: 0.6701 -0.02 (-2.67%)
NASDAQ:ARDS (2/3/2023, 7:25:26 PM)+0.02 (+2.56%)
GICS Sector | Health Care | ||
GICS Industry | Biotechnology |
Valuation | Growth | ||
Profitability | Health | ||
Dividend |
Earnings (Last) | 11-21 2022-11-21/amc | Earnings (Next) | 03-29 2023-03-29/amc |
Ins Owners | 24.84% | Inst Owners | 9.51% |
Market Cap | 14.32M | Shares | 20.80M |
PE | N/A | Fwd PE | N/A |
Dividend Yield | N/A | Analysts | 80 |
IPO | 08-14 2018-08-14 |
Find more stocks on Nasdaq
Find more stocks on the USA
Find competitors from the same sector on the USA
Find competitors from the same industry on the USA
Find stocks with similar TA and Setup ratings on the USA
Find stocks with similar Fundamental rating on the USA
Find more growth stocks the USA
Find the competitors with the best technical ratings on the USA
Find the competitors with the best technical and setup ratings on the USA
Find the competitors with the best fundamentals on the USA
Find the competitors with the best valuation on the USA
Find the competitors with the best dividend on the USA
Find the competitors with the best analyst ratings on the USA
Aridis Pharmaceuticals, Inc. engages in the discovery and development of targeted immunotherapy using fully human monoclonal antibodies, or mAbs, to treat life-threatening infections. The company is headquartered in Los Gatos, California and currently employs 34 full-time employees. The company went IPO on 2018-08-14. The firm is focused on the discovery and development of targeted immunotherapy using fully human monoclonal antibodies (mAbs) to treat life-threatening infections. The firm's product pipeline is comprised of fully human mAbs targeting specific pathogens associated with life-threatening bacterial and viral infections, primarily hospital-acquired pneumonia (HAP), ventilator-associated pneumonia (VAP), cystic fibrosis and COVID-19. The firm's lead product candidate, AR-301, targets the alpha toxin produced by gram-positive bacteria Staphylococcus aureus (S. aureus), a common pathogen associated with HAP and VAP. Its clinical development activities are focused on AR-301, AR320, AR-701, and AR-501. Its MabIgX and lPEX discovery platforms enables the Company to rapidly screen, identify and optimize fully human therapeutic mAb product candidates directly from the B-cells of patients.
ARIDIS PHARMACEUTICALS INC
983 University Avenue, Bldg. B
Los Gatos CALIFORNIA 95032
P: 14083851742.0
CEO: Vu Truong
Employees: 34
Website: https://aridispharma.com
Let's have a look at the stocks with an unusual volume in today's session.
Let's have a look at the stocks with an unusual volume in today's session.
Aridis Pharmaceuticals (ARDS) monoclonal antibody therapy AR-301 failed the main goal in a phase 3 trial to treat Ventilator Associated Pneumonia ((VAP)) caused by Gram-positive...
We're starting off the day with an overview of the biggest pre-market stock movers that traders need to watch on Thursday!
LOS GATOS, Calif, Jan. 25, 2023 (GLOBE NEWSWIRE) -- Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS) today announced top-line results from the AR-301-002...
It's time to start off the day with an overview of the biggest pre-market stock movers traders need to know about on Wednesday!
Here you can normally see the latest stock twits on ARDS, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.
Example Twits: